Hans Brevinge

Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer

E. Lindholm, Hans Brevinge, E. Haglind · British journal of surgery · 2008 · 298 citations · Full text

Medicine, Oncology, Preventive Medicine +16

Results of Screening, Rescreening, and Follow-up in a Prospective Randomized Study for Detection of Colorectal Cancer by Fecal Occult Blood Testing: Results for 68,308 Subjects

J Kewenter, Hans Brevinge, Boel Engarås et al. · Scandinavian Journal of Gastroenterology · 1994 · 252 citations

Medicine, Oncology, Preventive Medicine +17

Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells.

Ke Zhang, Dan Baeckström, Hans Brevinge et al. · PubMed · 1996 · 90 citations

Life Sciences, Immunology, Oncology +16

Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study.

Peter Daneryd, Elisabeth Svanberg, Ulla Körner et al. · PubMed · 1998 · 86 citations

Medicine, Pharmacology, Pharmacotherapy +17

Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells

Ke Zhang, Dan Baeckström, Hans Brevinge et al. · Journal of Cellular Biochemistry · 1996 · 85 citations

Life Sciences, Immunology, Oncology +14